Skip to main content
. Author manuscript; available in PMC: 2010 Jan 14.
Published in final edited form as: Circ Heart Fail. 2008 Nov;1(4):227–233. doi: 10.1161/CIRCHEARTFAILURE.108.785501

Table 1.

Clinical Characteristics of the Study Population

Baseline Characteristic N=30
Demographics
 Age, years 58±13
 Female 3 (10)
 White 27 (90)
Etiology of heart failure
 Ischemic 15 (50)
 Nonischemic 15 (50)
NYHA class
 II 16 (53)
 III 11 (37)
 IV 3 (10)
Medical and device therapy
β-blocker 29 (97)
 ACEI or ARB 25 (83)
 Aldosterone antagonist 17 (57)
 Diuretics 30 (100)
 Digoxin 22 (73)
 Cardiac resynchronization therapy 8 (27)
Pulmonary function testing
 FEV1, % predicted 66±20
 FVC, % predicted 74±20
 DLCO, % predicted 64±19

Data are presented as mean±SD for continuous variables and n (%) for dichotomous variables.

NYHA indicates New York Heart Association; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; DLCO, diffusing limit for carbon monoxide.